Novartis Taps Ketchum for Pain Inhibitor
Charting the future of public relations
Holmes Report
CEO

Novartis Taps Ketchum for Pain Inhibitor

Novartis Pharmaceuticals has selected Ketchum to provide public relations support for its COX-2 pain inhibitor.

Paul Holmes

NEW YORK, November 1—Novartis Pharmaceuticals has selected Ketchum to provide public relations support for its COX-2 pain inhibitor, a new therapy in development that will compete in the highly competitive arthritis and pain category. Ketchum beat out Hill & Knowlton and Chamberlain Communications Group for the business.
 
Ketchum will handle all communications in the United States leading up to and through the launch of COX189, which is currently in clinical trials.
 
The account team will be led out of Ketchum’s New York office by Tom Jones, vice president and group manager.
View Style:

Load 3 More
comments powered by Disqus